See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

The chef was able to ring the victory bell to mark the end of her cancer treatment and is getting her tastebuds back. Here's ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...

FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not ...

Knowledge of the association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (OPSCC) is poor and ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted ...

Head and neck squamous cell carcinoma (HNSCC), the seventh most prevalent cancer globally, originates from the mucosal epithelium of the oral cavity, pharynx, and larynx. Traditional risk factors like ...